Skip to main content

Advertisement

SpringerLink
Log in

Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis

  • Review
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background

The role of neoadjuvant epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) targeted therapy for EGFR-mutated non-small cell lung cancer (NSCLC) is unclear. Previous studies have shown that EGFR-TKIs have excellent anti-tumor activity. However, almost all studies on neoadjuvant EGFR-TKI treatment for EGFR-mutated NSCLC have been non-randomized controlled trials with small sample sizes and different methods of statistical analysis, which may lead to a lack of valid metrics to assess the feasibility and safety of neoadjuvant EGFR-TKI treatment. This meta-analysis aimed to assess the efficacy and safety of neoadjuvant EGFR-TKI treatment for NSCLC patients with EGFR mutations.

Methods

Relevant studies were systematically searched in PubMed, Embase, and Web of Science databases. Results including objective response rate (ORR), complete resection rate (R0), downstaging rate, pathological complete response (PCR), major pathological response (MPR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were used for further analysis.

Results

This meta-analysis ultimately included 11 studies involving 344 patients with EGFR-positive mutations in NSCLC. In terms of tumor response, the pooled ORR was 57% (95% CI: 42%–73%), and in the Osimertinib subgroup, the pooled ORR was 80% (95% CI: 63%–98%). Analysis of studies that reported a downstaging rate showed the pooled downstaging rate of 41% (95% CI: 9%–74%) and the pooled downstaging rate of 74% (95% CI: 22%–100%) in the Osimertinib subgroup. In terms of surgical outcomes, the pooled pCR rate was 3% (95% CI: 0%–7%), the pooled MPR rate was 11% (95% CI: 6%–17%), and the pooled R0 resection rate was 91% (95% CI: 85%–95%). The most common adverse events associated with neoadjuvant therapy were rash and diarrhea. The pooled incidence of any grade of rash was 47.1% (95% CI: 25.4%–69.3%), and the pooled incidence of grade ≥ 3 rash was 0.6% (95% CI: 0.0%–2.5%). The pooled incidence of diarrhea of any grade was 28.8% (95% CI: 14.4%–45.4%), with the pooled incidence of grade ≥ 3 diarrhea of 0.2% (95% CI: 0.0%–1.6%). The pooled incidence of ≥ grade 3 adverse events was significantly lower.

Conclusions

Our meta-analysis confirmed the efficacy and safety of neoadjuvant EGFR-TKIs for the treatment of NSCLC patients with EGFR-positive mutations and that third-generation EGFR-TKIs were superior to first- and second-generation EGFR-TKIs in terms of shrinking tumor volume and lowering tumor stage; however, future large-scale and multicenter randomized controlled trials are needed to confirm this conclusion.

Systematic review registration

PROSPERO CRD42023466731

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

References

  1. Brennan P, Hainaut P, Boffetta P (2011) Genetics of lung-cancer susceptibility. Lancet Oncol 12(4):399–408

    Article  CAS  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30

    Article  PubMed  Google Scholar 

  3. Saw SPL, Ong BH, Chua KLM, Takano A, Tan DSW (2021) Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol 22(11):e501–e516

    Article  CAS  PubMed  Google Scholar 

  4. Preoperative chemotherapy for non-small-cell lung cancer (2014) A systematic review and meta-analysis of individual participant data. Lancet 383(9928):1561–1571

    Article  Google Scholar 

  5. Chong CR, Jänne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389–1400

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8(12):1197–1206

    Article  CAS  PubMed  Google Scholar 

  7. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128

    Article  CAS  PubMed  Google Scholar 

  8. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742

    Article  CAS  PubMed  Google Scholar 

  9. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246

    Article  CAS  PubMed  Google Scholar 

  10. Yue D, Xu S, Wang Q et al (2018) Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med 6(11):863–873

    Article  CAS  PubMed  Google Scholar 

  11. Zhong WZ, Wang Q, Mao WM et al (2018) Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 19(1):139–148

    Article  CAS  PubMed  Google Scholar 

  12. Zhong WZ, Chen KN, Chen C et al (2019) Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol 37(25):2235–2245

    Article  CAS  PubMed  Google Scholar 

  13. Zhong WZ, Yan HH, Chen KN et al (2023) Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct Target Ther 8(1):76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247

    Article  CAS  PubMed  Google Scholar 

  15. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181

    Article  PubMed  Google Scholar 

  16. Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bian D, Sun L, Hu J et al (2023) Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study. Nat Commun 14(1):4655

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lv C, Fang W, Wu N et al (2023) Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung Cancer 178:151–156

    Article  CAS  PubMed  Google Scholar 

  19. Lara-Guerra H, Waddell TK, Salvarrey MA et al (2009) Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol 27(36):6229–6236

    Article  CAS  PubMed  Google Scholar 

  20. Peled N, Roisman LC, Levison E et al (2023) Neoadjuvant osimertinib followed by sequential definitive radiation therapy and/or surgery in stage III epidermal growth factor receptor-mutant non-small cell lung cancer: an open-label, single-arm, phase 2 study. Int J Radiat Oncol Biol Phys 117(1):105–114

    Article  PubMed  Google Scholar 

  21. Wang T, Liu Y, Zhou B et al (2016) Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes. Onco Targets Ther 9:1735–1741

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Xiong L, Li R, Sun J et al (2019) Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, Phase II study. Oncologist 24(2):157–157e64

    Article  CAS  PubMed  Google Scholar 

  23. Hu Y, Ren S, Yang L et al (2022) Osimertinib as neoadjuvant therapy for resectable non-small cell lung cancer: a case series. Front Pharmacol 13:912153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhang Y, Fu F, Hu H et al (2021) Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study. J Thorac Cardiovasc Surg 161(2):434–442.e2

    Article  PubMed  Google Scholar 

  25. Zhong W, Yang X, Yan H et al (2015) Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol 8:54

    Article  PubMed  PubMed Central  Google Scholar 

  26. Rizvi NA, Rusch V, Pao W et al (2011) Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res 17(10):3500–3506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Daly ME, Singh N, Ismaila N et al (2022) Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol 40(12):1356–1384

    Article  PubMed  Google Scholar 

  28. Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T (2021) Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol 18(9):547–557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Forde PM, Chaft JE, Smith KN et al (2018) Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 378(21):1976–1986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Provencio M, Nadal E, Insa A et al (2020) Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 21(11):1413–1422

    Article  CAS  PubMed  Google Scholar 

  31. Provencio M, Serna-Blasco R, Nadal E et al (2022) Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol 40(25):2924–2933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Forde PM, Spicer J, Lu S et al (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386(21):1973–1985

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874

    Article  CAS  PubMed  Google Scholar 

  34. Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24(1):54–59

    Article  CAS  PubMed  Google Scholar 

  35. Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222

    Article  CAS  PubMed  Google Scholar 

  36. Gilligan D, Nicolson M, Smith I et al (2007) Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 369(9577):1929–1937

    Article  CAS  PubMed  Google Scholar 

  37. Shi Y, Chen G, Wang X et al (2022) Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med 10(11):1019–1028

    Article  CAS  PubMed  Google Scholar 

  38. Shi Y, Chen G, Wang X et al (2022) Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study. J Thorac Oncol 17(11):1297–1305

    Article  CAS  PubMed  Google Scholar 

  39. Soria JC, Felip E, Cobo M et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16(8):897–907

    Article  CAS  PubMed  Google Scholar 

  40. Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113–125

    Article  CAS  PubMed  Google Scholar 

  41. Cho BC, Chewaskulyong B, Lee KH et al (2019) Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA asian subset. J Thorac Oncol 14(1):99–106

    Article  CAS  PubMed  Google Scholar 

  42. Cheng Y, He Y, Li W et al (2021) Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China: a randomized study. Target Oncol 16(2):165–176

    Article  PubMed  PubMed Central  Google Scholar 

  43. Reungwetwattana T, Nakagawa K, Cho BC et al (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018:Jco2018783118

    Google Scholar 

  44. Wu YL, John T, Grohe C et al (2022) Postoperative chemotherapy use and outcomes from ADAURA: Osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 17(3):423–433

    Article  CAS  PubMed  Google Scholar 

  45. Herbst RS, Wu YL, John T et al (2023) Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the Phase III randomized ADAURA trial. J Clin Oncol 41(10):1830–1840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by grants from the National Natural Science Foundation of China (No.82260015) and Beijing Xisike Clinical Oncology Research Foundation (Y-2019AZMS-0350).

Author information

Author notes

  1. Fei Xu and Juntao Zou contributed equally to this work and should be considered co-correspondence.

Authors and Affiliations

  1. Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

    Zhuchen Yu, Fei Xu & Juntao Zou

Authors
  1. Zhuchen Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juntao Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FX designed the conception and methodology. ZCY and JTZ wrote the original draft and collected the data for figure legends. ZCY and JTZ performed the data analysis and revised the manuscript. All authors approved of the final version of the manuscript.

Corresponding authors

Correspondence to Fei Xu or Juntao Zou.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, Z., Xu, F. & Zou, J. Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis. Eur J Clin Pharmacol 80, 505–517 (2024). https://doi.org/10.1007/s00228-024-03620-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-024-03620-w

Keywords

Search

Navigation